Urinary C3M

There is 1 paper on urinary C3M in aging research: 1 trial in people.

Biomarker

1 paper studies it3 findings

See all 1 papers on urinary C3M

“Urinary C3M was positively associated with future eGFR, with a steeper slope in the combination therapy group than in the RASi monotherapy group (P < 0.001).”
Combination therapy of RAS inhibition and glucagon-like peptide-1 receptor agonist improves a marker of kidney fibrosis in people with type 2 diabetesAmerican journal of physiology. Cell physiology2026doi:10.1152/ajpcell.00526.2025
  • Human trial1

Interventions

2

Renin-angiotensin system inhibitors

downin humans1

1 study
  1. Renin-angiotensin system inhibitors are linked with lower urinary C3M in humans (RASi monotherapy group; levels stable with combination therapy).

    “urinary C3M levels remained stable, whereas levels decreased with RASi monotherapy, suggesting altered kidney ECM turnover.”

    HumansRASi monotherapy group; levels stable with combination therapykidneyn = 229

    Combination therapy of RAS inhibition and glucagon-like peptide-1 receptor agonist improves a marker of kidney fibrosis in people with type 2 diabetes

    American journal of physiology. Cell physiology

More on Renin-angiotensin system inhibitors

Renin-angiotensin system inhibitors + GLP-1 receptor agonists

upin humans1

1 study
  1. Renin-angiotensin system inhibitors + GLP-1 receptor agonists are linked with higher urinary C3M in humans (compared with RASi monotherapy).

    “Combination therapy (RASi + GLP-1 RA) was associated with higher urinary C3M levels compared with RASi monotherapy (P = 0.036).”

    Humanscompared with RASi monotherapykidneyn = 229

    Combination therapy of RAS inhibition and glucagon-like peptide-1 receptor agonist improves a marker of kidney fibrosis in people with type 2 diabetes

    American journal of physiology. Cell physiology

More on Renin-angiotensin system inhibitors + GLP-1 receptor agonists

Associations

1

Estimated glomerular filtration rate

upin humans1

1 study
  1. Urinary C3M predicts estimated glomerular filtration rate in humans (steeper slope in the combination therapy group).

    “Urinary C3M was positively associated with future eGFR, with a steeper slope in the combination therapy group than in the RASi monotherapy group (P < 0.001).”

    Humanssteeper slope in the combination therapy groupkidneyn = 229

    Combination therapy of RAS inhibition and glucagon-like peptide-1 receptor agonist improves a marker of kidney fibrosis in people with type 2 diabetes

    American journal of physiology. Cell physiology

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months